RxDoctor Payments Data

Rajan Patel, MD

Neurology · Arroyo Grande, CANPI 1700197217

Payments from drug & device makers

$1,535in general payments, 2019–2025

Across 84 payments — averaging $18.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$363
  • Sunovion Pharmaceuticals Inc.$200
  • Novartis$110
  • Acadia Pharmaceuticals Inc$93
  • Neurocrine Biosciences, Inc.$84
  • Abbott$73
  • plus $611 from 18 others

What the payments were for

  • Speaking & faculty fees$614%
  • Food & beverage$1,39991%
  • Education$755%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,535 in reported general payments places this provider in the 50th percentile of 1,996 neurology providers in California.

See all neurology providers in California

Medicare billing

Part B allowed, 2024
$184,432
Medicare patients
436
Services billed
10,084

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NuplazidPimavanserin Tartrate25$122,777
UbrelvyUbrogepant60$105,132
RytaryCarbidopa/Levodopa52$99,932
AptiomEslicarbazepine Acetate28$92,121
FycompaPerampanel47$63,935
Aimovig AutoinjectorErenumab-Aooe77$59,035
Lacosamide200$52,974
Nurtec OdtRimegepant Sulfate30$52,592
Dimethyl Fumarate19$48,693
Emgality PenGalcanezumab-Gnlm56$44,623
Lamictal XrLamotrigine12$44,374
Dalfampridine ErDalfampridine65$30,350
NamzaricMemantine Hcl/Donepezil Hcl16$27,026
GocovriAmantadine Hcl13$20,500
Levetiracetam181$17,179

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy, Namzaric, Qulipta$363$144,26587 claims
Acadia Pharmaceuticals IncNuplazid$93$122,77725 claims
Amneal Pharmaceuticals LLCRytary$19$99,93252 claims
Sunovion Pharmaceuticals Inc.Aptiom$200$92,12128 claims
UCB, Inc.Vimpat$33$13,09112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 1,996 neurology providers in California.

Other neurology in Arroyo Grande

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →